Successful Resection of a Gastrointestinal Stromal Tumor in the Pelvis with Imatinib Mesylate as Neoadjuvant Therapy by 中島, 信幸 et al.
Title術前イマチニブ投与により手術が可能となった骨盤内GISTの1例
Author(s)
中島, 信幸; 加藤, 成一; 臼井, 幸男; 篠崎, 哲男; 添田, 宗市;
川上, 正能; 金, 伯士; 花井, 一也; 星, 昭夫; 野本, 剛史; 寺地,
敏郎; 貞廣, 荘太郎








可能となった骨盤内 GIST の 1例
中島 信幸1，加藤 成一1，臼井 幸男1，篠崎 哲男1
添田 宗市1，川上 正能1，金 伯士1，花井 一也1
星 昭夫1，野本 剛史1，寺地 敏郎1，貞廣荘太郎2
1東海大学医学部外科学系泌尿器科，2東海大学医学部外科学系消化器外科
SUCCESSFUL RESECTION OF A GASTROINTESTINAL STROMAL
TUMOR IN THE PELVIS WITH IMATINIB MESYLATE
AS NEOADJUVANT THERAPY
Nobuyuki Nakajima1, Seiichi Kato1, Yukio Usui1, Tetsuo Shinozaki1,
Shuichi Soeda1, Masayoshi Kawakami1, Hakushi Kim1, Kazuya Hanai1,
Akio Hoshi1, Takeshi Nomoto1, Toshiro Terachi1 and Sotaro Sadahiro2
1The Department of Urology, Tokai University
2The Department of General Surgery, Tokai University
We report a case of marginally resectable gastrointestinal stromal tumor (GIST) in the pelvis treated
with neoadjuvant intent before subsequent successful surgical resection. A 46-year old man presented with
urinary frequency and rectal discomfort with tenesmus. Computed tomography (CT) and magnetic
resonance imaging (MRI) revealed a 12 cm diameter mass between the bladder and rectum and the margin
of the tumor and prostate was unclear. No metastases were evident. Trans-rectal needle core biopsy
conﬁrmed c-kit positive GIST. Because of the locally advanced nature of the tumor, immediate surgical
resection would have required total pelvic exenteration with eternal colostomy and urinary diversion.
Therefore, the patient was treated with imatinib mesylate 400 mg daily in anticipation of adequate tumor size
reduction to enable a more simpliﬁed surgical approach. After 3 months of imatinib therapy, MRI
demonstrated a reduction in tumor size of 60%. Consequently, a complete surgical resection including the
bladder, prostate and part of the sigmoid colon with temporary ileostomy and ileal conduit was performed.
Pathological ﬁndings of the resected specimen showed widespread degeneration with cystic changes, necrosis,
and hypocellularlity, as well as nodules of residual viable c-kit positive tumor cells. The patient has been
treated with imatinib mesylate for 39 months following the operation without tumor recurrence.
(Hinyokika Kiyo 57 : 135-139, 2011)
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常を認めなかった．CEA 4.5 ng/ml，AFP 3.1 ng/ml，
CA19-9 15.6 U/ml，PSA 3.99 ng/ml と腫瘍マーカー
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Fig. 2. MRI T2W images revealed change of the tumor size through neoadjuvant therapy with imatinib mesylate, and
a 60％ reduction in tumor size after three months of imatinib therapy.
は正常であった．腹部 CT では，膀胱と直腸の間に造




し，病理結果は gastrointestinal stromal tumor (GIST），
spindle cell type KIT (＋），CD34 (＋），α-SMA (−），
desmin (−），S−100 (＋/−），vimentin (＋），MIB-1
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Fig. 3. Comparison of microscopic ﬁnding between the biopsy specimen and the excised specimen. Upper
stand―The microscopic ﬁnding of the biopsy specimen shows many c-kit positive spindle shaped
tumor cells with nuclear atypia (magniﬁcation in the small window). Lower stand―The
microscopic ﬁnding of the excised specimen shows widespread degeneration with cystic change,














れるが，GIST では KIT 蛋白が非常に多く発現して
おり，細胞の異常増殖が誘発されて腫瘍を形成す











で，CR (complete response) と PR (partial response) と














中島，ほか : GIST・メシル酸イマチニブ 137
している可能性が疑われる，いわゆる，marginally








































marginally resectable GIST では，少なくとも 3年程度
の術後補助療法が必要と考える．
結 語
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